Dupixent Asthma denied as not medically necessary by Aetna?

Aetna's specific coverage criteria for dupixent asthma are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Dupixent for Asthma as Not Medically Necessary — and How to Appeal

Aetna medical-necessity denials for dupilumab (Dupixent) in asthma typically occur when the plan concludes that submitted documentation does not demonstrate the severity of disease, the prior treatment failures, or the clinical profile required by its coverage policy. These are almost always documentation gaps rather than true clinical disqualifications — and they are among the most successfully appealed denial types.

### Why This Denial Is Appealable

Medical necessity is a clinical determination that must be made by a licensed clinician reviewing your complete record — not an automated check of submitted claims data. Under ERISA §503 and ACA §2719, Aetna must provide you with the specific clinical criteria its reviewer applied, and you have the right to a full-and-fair review in which a qualified clinician re-evaluates your case with complete documentation. External review is also available and frequently reverses medical-necessity denials for dupilumab when the record is complete.

### Your Appeal Timeline

• Internal appeal: File within the deadline on your denial notice (commonly 180 days for ERISA plans). Decisions within 30–60 days; expedited within 72 hours for urgent situations.
• External review: After internal denial, approximately four months to request independent external review. Expedited review available for urgent cases.

### Documentation to Gather

1. Diagnosis confirmation — specialist evaluation notes, pulmonary function test results, and chart documentation establishing the diagnosis and severity of asthma. 2. Prior treatment history with dates and outcomes — a comprehensive, dated record of every controller therapy, oral corticosteroid course, and prior biologic tried, with documented response or reason for discontinuation. 3. Clinical severity documentation — exacerbation frequency and severity, emergency department or hospital visits, oral corticosteroid burden, validated symptom scores, and quality-of-life measures from your chart. 4. Phenotype documentation — laboratory and clinical records supporting the inflammatory profile described in the FDA-approved indication for dupilumab. 5. Prescriber medical-necessity letter — your allergist or pulmonologist should map your clinical presentation to each criterion in Aetna's published coverage policy, explain why standard therapies have been inadequate, and reference the FDA-approved indication and the applicable professional society guideline organization (e.g., GINA or NAEPP framework).

### Criteria-Mapping Structure

Obtain Aetna's clinical policy for dupilumab in asthma (it should have been attached to your denial or is available on request). Build a point-by-point response:

| Aetna Policy Criterion | Your Chart Evidence | |---|---| | Confirmed moderate-to-severe asthma diagnosis | [PFT date, specialist note] | | Qualifying phenotype per FDA label | [Lab or clinical documentation] | | Inadequate control on required prior therapies | [Each therapy, date, outcome] | | Prescribing specialist requirement | [Physician's credentials and specialty] |

Every unmet criterion identified in the denial letter should be addressed with a specific chart reference. Attach the FDA-approved prescribing information for dupilumab as a primary-source exhibit.